Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Skin Specialists PC

Neither a doctor nor a teaching hospital

Research payments

$3,743,483

788 payments

Through program year 2025, Skin Specialists PC is reported as receiving $3,743,483 in research payments, across 788 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $849,624 107
2024 Research $978,996 223
2023 Research $480,772 157
2022 Research $291,175 66
2021 Research $328,210 70
2020 Research $301,571 71
2019 Research $513,133 94

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $957,579 156 payments
  2. Pfizer Inc. $560,928 188 payments
  3. Eli Lilly and Company $354,000 19 payments
  4. Novartis Pharmaceuticals Corporation $336,312 6 payments
  5. Aclaris Therapeutics, Inc. $273,592 36 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $244,829 27 payments
  7. Janssen Research & Development, LLC $226,635 61 payments
  8. Amgen Inc. $209,436 9 payments
  9. Allergan Inc. $154,576 27 payments
  10. Endo Pharmaceuticals Inc. $120,163 23 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $246,693 3 payments
  2. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $226,037 18 payments
  3. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $223,312 16 payments
  4. A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $190,770 2 payments
  5. Interchangeability Study - ABP 654 $169,243 1 payment
  6. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $140,155 11 payments
  7. A Phase 3B, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy $115,445 20 payments
  8. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $109,719 18 payments
  9. A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis $107,402 15 payments
  10. A Phase 2B3 Randomized Doubleblind Placebocontrolled Doseranging Study to Investigate the Efficacy and Safety of Pf06651600 in Adult and Adolescent Alopecia Areata Aa Subjects With 50 Or Greater Scalp Hair Loss $104,389 35 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record